Terms: = Lymphoma AND MYC, c-Myc, 4609, ENSG00000136997 AND Clinical Outcome
85 results:
1. Non-IG::myc in diffuse large B-cell lymphoma confers variable genomic configurations and myc transactivation potential.
Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
[TBL] [Abstract] [Full Text] [Related]
2. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract] [Full Text] [Related]
3. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
Wang Y; Shi Q; Shi ZY; Tian S; Zhang MC; Shen R; Fu D; Dong L; Yi HM; Ouyang BS; Mu RJ; Cheng S; Wang L; Xu PP; Zhao WL
Blood Adv; 2024 Apr; 8(7):1587-1599. PubMed ID: 38170757
[TBL] [Abstract] [Full Text] [Related]
4. RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
Kubota H; Ueno H; Tasaka K; Isobe T; Saida S; Kato I; Umeda K; Hiwatari M; Hasegawa D; Imamura T; Kakiuchi N; Nannya Y; Ogawa S; Hiramatsu H; Takita J
Blood Adv; 2024 Mar; 8(5):1258-1271. PubMed ID: 38127276
[TBL] [Abstract] [Full Text] [Related]
5. The Clinicopathologic Features and Molecular Signatures of Blastoid High-Grade B Cell lymphoma, Not Otherwise Specified.
Qiu L; Lin P; Khanlari M; Xu J; Cohen EN; Garces S; Miranda RN; Wang W; Fang H; Bueso-Ramos CE; Medeiros LJ; Li S
Mod Pathol; 2023 Dec; 36(12):100349. PubMed ID: 37820764
[TBL] [Abstract] [Full Text] [Related]
6. myc protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract] [Full Text] [Related]
7. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.
Kumar A; Taghi Khani A; Duault C; Aramburo S; Sanchez Ortiz A; Lee SJ; Chan A; McDonald T; Huang M; Lacayo NJ; Sakamoto KM; Yu J; Hurtz C; Carroll M; Tasian SK; Ghoda L; Marcucci G; Gu Z; Rosen ST; Armenian S; Izraeli S; Chen CW; Caligiuri MA; Forman SJ; Maecker HT; Swaminathan S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217248
[TBL] [Abstract] [Full Text] [Related]
8. Lack of reproducibility of histopathological features in myc-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium.
Natkunam Y; de Jong D; Farinha P; Gaulard P; Klapper W; Rosenwald A; Sander B; Tooze R; Advani R; Burton C; Gribben JG; Kersten MJ; Kimby E; Lenz G; Molina T; Morschhauser F; Scott D; Sehn L; Stevens W; Clear A; Baia M; Habi A; Elsensohn MH; Langlois-Jacques C; Maucort-Boulch D; Calaminici M
Histopathology; 2023 Jun; 82(7):1105-1111. PubMed ID: 36849712
[TBL] [Abstract] [Full Text] [Related]
9. Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of myc target genes and poor clinical outcome following R-CHOP therapy.
Tyryshkin K; Moore A; Good D; Popov J; Crocker S; Rauh MJ; Baetz T; LeBrun DP
Leuk Lymphoma; 2023 Jan; 64(1):119-129. PubMed ID: 36336953
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological Characterization of Primary Diffuse Large B-Cell lymphoma of the Central Nervous System.
Woo HY; Chae SW; DO SI; Na K
Anticancer Res; 2022 Nov; 42(11):5601-5608. PubMed ID: 36288864
[TBL] [Abstract] [Full Text] [Related]
11. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell lymphoma.
Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
[TBL] [Abstract] [Full Text] [Related]
12. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-myc rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
13. Combined Detection of Copy Number Variations of mycN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
[TBL] [Abstract] [Full Text] [Related]
14. AID is a poor prognostic marker of high-grade B-cell lymphoma with myc and BCL2 and/or BCL6 rearrangements.
Miyaoka M; Kikuti YY; Carreras J; Itou A; Ikoma H; Tomita S; Shiraiwa S; Ando K; Nakamura N
Pathol Int; 2022 Jan; 72(1):35-42. PubMed ID: 34727403
[TBL] [Abstract] [Full Text] [Related]
15. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract] [Full Text] [Related]
16. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
[TBL] [Abstract] [Full Text] [Related]
17. CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.
Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
[TBL] [Abstract] [Full Text] [Related]
18. Is acute lymphoblastic leukemia with mature B-cell phenotype and
Hidalgo-Gómez G; Palacio-Garcia C; Gallur L; Blanco A; Tazón-Vega B; Saumell S; Martínez N; Murillo L; Murciano T; Velasco P; Bosch F; Diaz-Heredia C; Ortega M
Leuk Lymphoma; 2021 Sep; 62(9):2202-2210. PubMed ID: 33827367
[TBL] [Abstract] [Full Text] [Related]
19. Frequency Of Double Expressor lymphoma In A Tertiary Care Hospital.
Hassan M; Khattak MT; Qamar MA; Javed S; Saeed SU
J Ayub Med Coll Abbottabad; 2021; 33(1):44-48. PubMed ID: 33774953
[TBL] [Abstract] [Full Text] [Related]
20. Aggressive B-cell lymphoma with myc/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract] [Full Text] [Related]
[Next]
